Physician profile
John Cuthriell
NPI 1235991506
$1,243.01
in general payments reported to CMS, 2019-2025
18 companies · $819 in 2025
The $819 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $424 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $207.08 | 2024-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $170.23 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $128.91 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.50 | 2024-2025 | Xifaxan |
| Pfizer INC. | $112.98 | 2024-2025 | |
| Corcept Therapeutics | $100.06 | 2024-2025 | Korlym |
| Abbvie INC. | $79.74 | 2025 | |
| Biosense Webster, INC. | $71.98 | 2025 | Carto 3 |
| Amgen INC. | $50.25 | 2025 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $38.16 | 2024-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $28.37 | 2025 | |
| Boston Scientific Corporation | $26.05 | 2024 | Watchman Flx |
| Axsome Therapeutics, INC. | $24.87 | 2025 | Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $20.92 | 2025 | Trintellix |
| Esperion Therapeutics, INC. | $16.50 | 2024 | Nexletol |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $16.12 | 2025 | Dyanavel Xr |
| Eisai INC. | $15.46 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $13.83 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cuthriell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.